U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Chronic Myelomonocytic Leukemia-1

MedGen UID:
234148
•Concept ID:
C1333043
•
Neoplastic Process

Definition

A chronic myelomonocytic leukemia characterized by the presence of less than 10 percent blasts in the bone marrow and less than 5 percent blasts in the peripheral blood. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVChronic Myelomonocytic Leukemia-1

Professional guidelines

PubMed

A systematic review and meta-analysis of the efficacy and adverse events of azacitidine-plus-lenalidomide treatment for patients with acute myeloid leukemia, myelodysplastic syndromes and chronic myelomonocytic leukemia (1).
Kunacheewa C, Thongthang P, Ungprasert P, Utchariyaprasit E, Owattanapanich W
Hematology 2019 Dec;24(1):498-506. doi: 10.1080/16078454.2019.1631425. PMID: 31221030
Therapy-related myeloid neoplasms following treatment with radioiodine.
Schroeder T, Kuendgen A, Kayser S, Kröger N, Braulke F, Platzbecker U, Klärner V, Zohren F, Haase D, Stadler M, Schlenk R, Czibere AG, Bruns I, Fenk R, Gattermann N, Haas R, Kobbe G, Germing U
Haematologica 2012 Feb;97(2):206-12. Epub 2011 Oct 11 doi: 10.3324/haematol.2011.049114. PMID: 21993688Free PMC Article
Combination of 5-azacytidine and thalidomide for the treatment of myelodysplastic syndromes and acute myeloid leukemia.
Raza A, Mehdi M, Mumtaz M, Ali F, Lascher S, Galili N
Cancer 2008 Oct 1;113(7):1596-604. doi: 10.1002/cncr.23789. PMID: 18720364

Recent clinical studies

Etiology

A systematic review and meta-analysis of the efficacy and adverse events of azacitidine-plus-lenalidomide treatment for patients with acute myeloid leukemia, myelodysplastic syndromes and chronic myelomonocytic leukemia (1).
Kunacheewa C, Thongthang P, Ungprasert P, Utchariyaprasit E, Owattanapanich W
Hematology 2019 Dec;24(1):498-506. doi: 10.1080/16078454.2019.1631425. PMID: 31221030
p53 Protein expression in chronic myelomonocytic leukemia-1 correlates with progression to leukemia and a poor prognosis.
Hattori N, Fukuchi K, Nakamaki T, Homma M, Ariizumi H, Nakashima H, Maeda T, Saito B, Yamochi-Onizuka T, Yanagisawa K, Matsuda I, Ota H, Tomoyasu S
Acta Haematol 2011;125(4):242-6. Epub 2011 Feb 18 doi: 10.1159/000323571. PMID: 21335959
Chronic myelomonocytic leukemia following refractory anemia with sideroblasts: report of two cases.
Bursztyn B, Douer D, Ramot B
Eur J Haematol 1987 Feb;38(2):197-9. doi: 10.1111/j.1600-0609.1987.tb01161.x. PMID: 3474153

Diagnosis

TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia.
Kosmider O, Gelsi-Boyer V, Ciudad M, Racoeur C, Jooste V, Vey N, Quesnel B, Fenaux P, Bastie JN, Beyne-Rauzy O, Stamatoulas A, Dreyfus F, Ifrah N, de Botton S, Vainchenker W, Bernard OA, Birnbaum D, Fontenay M, Solary E; Groupe Francophone des Myélodysplasies
Haematologica 2009 Dec;94(12):1676-81. Epub 2009 Oct 1 doi: 10.3324/haematol.2009.011205. PMID: 19797729Free PMC Article

Therapy

A systematic review and meta-analysis of the efficacy and adverse events of azacitidine-plus-lenalidomide treatment for patients with acute myeloid leukemia, myelodysplastic syndromes and chronic myelomonocytic leukemia (1).
Kunacheewa C, Thongthang P, Ungprasert P, Utchariyaprasit E, Owattanapanich W
Hematology 2019 Dec;24(1):498-506. doi: 10.1080/16078454.2019.1631425. PMID: 31221030
Combination of 5-azacytidine and thalidomide for the treatment of myelodysplastic syndromes and acute myeloid leukemia.
Raza A, Mehdi M, Mumtaz M, Ali F, Lascher S, Galili N
Cancer 2008 Oct 1;113(7):1596-604. doi: 10.1002/cncr.23789. PMID: 18720364

Prognosis

Mutational hierarchies in myelodysplastic syndromes dynamically adapt and evolve upon therapy response and failure.
Mossner M, Jann JC, Wittig J, Nolte F, Fey S, Nowak V, Obländer J, Pressler J, Palme I, Xanthopoulos C, Boch T, Metzgeroth G, Röhl H, Witt SH, Dukal H, Klein C, Schmitt S, Gelß P, Platzbecker U, Balaian E, Fabarius A, Blum H, Schulze TJ, Meggendorfer M, Haferlach C, Trumpp A, Hofmann WK, Medyouf H, Nowak D
Blood 2016 Sep 1;128(9):1246-59. Epub 2016 Jun 6 doi: 10.1182/blood-2015-11-679167. PMID: 27268087
p53 Protein expression in chronic myelomonocytic leukemia-1 correlates with progression to leukemia and a poor prognosis.
Hattori N, Fukuchi K, Nakamaki T, Homma M, Ariizumi H, Nakashima H, Maeda T, Saito B, Yamochi-Onizuka T, Yanagisawa K, Matsuda I, Ota H, Tomoyasu S
Acta Haematol 2011;125(4):242-6. Epub 2011 Feb 18 doi: 10.1159/000323571. PMID: 21335959

Clinical prediction guides

t(3;8)(q26.2;q24) Often Leads to MECOM/MYC Rearrangement and Is Commonly Associated with Therapy-Related Myeloid Neoplasms and/or Disease Progression.
Tang G, Hu S, Wang SA, Xie W, Lin P, Xu J, Toruner G, Zhao M, Gu J, Doty M, Li S, Medeiros LJ, Tang Z
J Mol Diagn 2019 Mar;21(2):343-351. Epub 2018 Dec 19 doi: 10.1016/j.jmoldx.2018.10.005. PMID: 30576868
Mutational hierarchies in myelodysplastic syndromes dynamically adapt and evolve upon therapy response and failure.
Mossner M, Jann JC, Wittig J, Nolte F, Fey S, Nowak V, Obländer J, Pressler J, Palme I, Xanthopoulos C, Boch T, Metzgeroth G, Röhl H, Witt SH, Dukal H, Klein C, Schmitt S, Gelß P, Platzbecker U, Balaian E, Fabarius A, Blum H, Schulze TJ, Meggendorfer M, Haferlach C, Trumpp A, Hofmann WK, Medyouf H, Nowak D
Blood 2016 Sep 1;128(9):1246-59. Epub 2016 Jun 6 doi: 10.1182/blood-2015-11-679167. PMID: 27268087
TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia.
Kosmider O, Gelsi-Boyer V, Ciudad M, Racoeur C, Jooste V, Vey N, Quesnel B, Fenaux P, Bastie JN, Beyne-Rauzy O, Stamatoulas A, Dreyfus F, Ifrah N, de Botton S, Vainchenker W, Bernard OA, Birnbaum D, Fontenay M, Solary E; Groupe Francophone des Myélodysplasies
Haematologica 2009 Dec;94(12):1676-81. Epub 2009 Oct 1 doi: 10.3324/haematol.2009.011205. PMID: 19797729Free PMC Article
Combination of 5-azacytidine and thalidomide for the treatment of myelodysplastic syndromes and acute myeloid leukemia.
Raza A, Mehdi M, Mumtaz M, Ali F, Lascher S, Galili N
Cancer 2008 Oct 1;113(7):1596-604. doi: 10.1002/cncr.23789. PMID: 18720364
Chronic myelomonocytic leukemia following refractory anemia with sideroblasts: report of two cases.
Bursztyn B, Douer D, Ramot B
Eur J Haematol 1987 Feb;38(2):197-9. doi: 10.1111/j.1600-0609.1987.tb01161.x. PMID: 3474153

Recent systematic reviews

A systematic review and meta-analysis of the efficacy and adverse events of azacitidine-plus-lenalidomide treatment for patients with acute myeloid leukemia, myelodysplastic syndromes and chronic myelomonocytic leukemia (1).
Kunacheewa C, Thongthang P, Ungprasert P, Utchariyaprasit E, Owattanapanich W
Hematology 2019 Dec;24(1):498-506. doi: 10.1080/16078454.2019.1631425. PMID: 31221030

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...